Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2014 Sep 3;32(39):4954-9. doi: 10.1016/j.vaccine.2014.07.024. Epub 2014 Jul 27.

The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children.

Author information

1
Department of Public Health, Ben-Gurion University of the Negev, Israel. Electronic address: nataliag@post.bgu.ac.il.
2
Clalit Research Institute and Health Policy Planning Department, Chief Physician Office, Clalit Health Services, Israel.
3
Department of Public Health, Ben-Gurion University of the Negev, Israel.
4
Department of Public Health, Ben-Gurion University of the Negev, Israel; Clalit Research Institute and Health Policy Planning Department, Chief Physician Office, Clalit Health Services, Israel.

Abstract

BACKGROUND:

It was previously demonstrated that MMRV vaccine causes a higher rate of febrile convulsions (FC) compared to the MMR vaccine. Additional risk factors for FC include age, familial tendency, day care attendance, viral diseases, complications at birth and developmental delay.

OBJECTIVE:

We evaluated the relative and attributable risk of FC for vaccinees' age, ethnicity, low birth weight, preterm birth and MMRV vaccination in 10-24 months old children.

METHODS:

Data on medical history and vaccination were extracted from data warehouses of Clalit Health Services and Israel's Ministry of Health and linked on an individual record level for 90,294 MMR- and 8344 MMRV-vaccinees. A retrospective study design was used to reveal the risk factors associated with FC in study participants.

RESULTS:

During the second week after immunization, an elevated relative risk of FC was demonstrated in MMRV-recipients (adjusted RR=2.16 (95%CI: 1.01; 4.64)). However, the cumulative incidence of FC during the entire 40-day observation period did not differ between the MMR and MMRV vaccinees. The MMRV-specific attributable risk of FC was not statistically significant at any point of observation period and was exceedingly low compared to other risk factors, equaling 5.3 FC cases per 10,000 vaccinees (95%CI: -1.4; 12.2).

DISCUSSION:

Our findings demonstrate that MMRV-associated FC in 10-24 months old contributes very marginally to the overall rate of FC in this population.

CONCLUSION:

Given the low number of MMRV-specific FC cases, their transient nature and the benefit of vaccination, the overall benefit-risk of the vaccine can be considered favourable. Nonetheless, the option of separate immunization with MMR+V should be offered to parents, in order to maintain sufficient vaccine uptake in the population.

KEYWORDS:

Adverse event; Febrile convulsions; MMRV; Vaccination

PMID:
25075803
DOI:
10.1016/j.vaccine.2014.07.024
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center